BioTechniques: The Great Taper: steroids’ symptoms and the resultant rise of new classes of anti-inflammatories
John H. Stone MD MPH, Chair of the Steritas Scientific Advisory Board, discusses steroid-toxicity with BioTechniques. Read more
EBR: Opportunities in IgG4-RD for novel steroid-sparing therapeutics
John H. Stone MD MPH, Chair of the Steritas Scientific Advisory Board, discusses advances in the diagnosis and treatment of this autoimmune disorder that was classified as a unique disease in 2003. ...
DDN: How drug discovery is moving beyond steroids
Drug Discovery News spoke with John Stone, MD MPH, Chair of the Scientific Advisory Board at Steritas, to discuss the origins and impact of the GTI. To read the full interview, click here.
APR: The Overexposure to Steroids for Asthma Patients
American Pharmaceutical Review publishes an article by John H. Stone, MD MPH, Chair of the Steritas Scientific Advisory Board. You can read the article here. Full reference: American Pharmaceutical ...
DD&D: The true cost of steroid-toxicity
John Stone, MD MPH, Chair of Steritas Scientific Board, discusses the true cost of steroid-toxicity with Drug Discovery & Development (DD&D). Read the full article here.
Pharmafocus: Opportunities to reduce steroid-toxicity and embrace new treatment options for autoimmune patients
Steritas' John Stone analyses the benefits that a quantifiable index system can have for researchers looking into steroid toxicity, and how this can allow them to work with larger sets of patient ...